Classement en actions
#25796
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Capitalisation boursière
$46.24M
Changement (1 jour)
-16.52%
Changement (1 an)
103.39%
Échange Edesa Biotech, Inc. (EDSA)
Le prix EDSA avec la capitalisation boursière de B
Capitalisation boursière de Edesa Biotech, Inc.(EDSA)
Capitalisation boursière: $46.24M
En August 2026, Edesa Biotech, Inc. a une capitalisation boursière de $46.24M. Cela fait de Edesa Biotech, Inc. la 25796th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Edesa Biotech, Inc. du 2010 au 2026
EDSA par rapport au top 5 des plus populaires stocks
| Prix pour EDSA |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.257T
|
+11,368,556.10%
|
|
|
|
|
$4.599T
|
+9,945,110.35%
|
|
|
|
|
$4.107T
|
+8,880,944.52%
|
|
|
|
|
$3.577T
|
+7,736,196.86%
|
|
|
|
|
$2.807T
|
+6,071,079.53%
|
